 Checkpoint Therapeutics Inc NASDAQ: CKPT announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma cSCC who are not candidates for curative surgery or radiation. The. 